Plain-English translation of NCT05097274 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →This trial is testing whether a newer imaging scan called FCH-PET-CT can detect prostate cancer spread better than the current standard approach (bone scan combined with MRI or CT scan). The study focuses on men who have prostate cancer and carry mutations in specific DNA repair genes—genetic changes that put them at higher risk for cancer. Researchers want to see if the newer imaging method finds cancer in more places, which could help guide treatment decisions.
Men with certain genetic mutations are more likely to have prostate cancer spread to other parts of their body, but doctors don't always catch this early with current imaging methods. This study exists to find out whether a newer imaging approach can detect spread more reliably, which could help doctors treat these patients more effectively.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will undergo imaging scans to help researchers compare how well the newer FCH-PET-CT scan works compared to standard imaging (bone scan and MRI or CT). You'll come for one or more visits where you'll receive these scans—similar to what you might have done already as part of your cancer care. The study involves no medication to take at home; it's focused on comparing imaging methods to see which detects cancer spread more accurately.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United Kingdom